Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: Poly(ethylene carbonate) (PEC) nanoparticles comprising pharmacologically active substances, their production method and their use for sustained release of the pharmacologically active agent after application are described.

Abstract: The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers, to poorly water-soluble salts of such bisphosphonates, to crystalline forms of the free compounds and the salts and to other related aspects, where the compounds are of the Formula (I), where R1 and R2 are as described in the specification. Compounds of the Formula (I) and their forms mentioned in the disclosure are useful for the treatment of bone-related disorders and cancer.

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.

Abstract: The invention relates to new crystalline forms of low water soluble salts of zoledronic acid, the process for preparation of these crystalline forms, compositions containing these crystalline forms, and the use of these crystalline forms in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the crystalline form of the free acid monohydrate of zoledronic acid, the process for preparation of the crystalline form of the free acid monohydrate of zoledronic acid, compositions containing the crystalline form of the free acid monohydrate of zoledronic acid, and the use of crystalline form of the free acid monohydrate of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.

Abstract: The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers. The depot formulation may be in the form of microparticles or implants. The depot formulations are useful for the treatment and prevention of proliferative diseases including cancer.

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).

Abstract: The invention relates to cationic block copolymers of formula A(-X-B)n, wherein A represents a hydrophilic polymer, B represents polyethyleneimine (PEI), X represents a bridge, n represents 1-200. The invention also relates to methods for producing the inventive cationic block polymers and to their use e.g. as a tenside and for complexing nucleic acids.

Abstract: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.

Abstract: The invention relates to cationic block copolymers of formula A(—X—B)n or C(—Y—D)m, wherein A represents a hydrophilic polymer, B represents polyethyleneimine (PEI), X represents a bridge, n represents 1-200, C represents PEI, D represents the residue of a polyethylene glycol, Y represents a bridge and m represents 1-200. The invention also relates to methods for producing the inventive cationic block polymers and to their use e.g. as a tenside and for complexing nucleic acids.

Abstract: The invention includes a plurality of first electrical pads which are supported on a first object which is configured to be supported in a first position, and a plurality of second electrical pads which are supported on a second object which is configured to be supported in a second position and adjacent to the first object. The first electrical pads are configured to electrically contact the second electrical pads while the objects are supported in the respective positions so as to electrically connect the objects together. Each of the objects is configured to be removed from the respective first and second positions by movement along parallel paths of movement in a first direction and are configured to be installed in the respective positions by movement along the paths in a second direction which is opposite the first direction. Furthermore, each object is configured to be installed into, or removed from, its respective supported position while the other object remains supported in its respective position.

Abstract: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.

Abstract: The invention includes a plurality of first electrical pads which are supported on a first object which is configured to be supported in a first position, and a plurality of second electrical pads which are supported on a second object which is configured to be supported in a second position and adjacent to the first object. The first electrical pads are configured to electrically contact the second electrical pads while the objects are supported in the respective positions so as to electrically connect the objects together. Each of the objects is configured to be removed from the respective first and second positions by movement along parallel paths of movement in a first direction and are configured to be installed in the respective positions by movement along the paths in a second direction which is opposite the first direction. Furthermore, each object is configured to be installed into, or removed from, its respective supported position while the other object remains supported in its respective position.

Abstract: An apparatus for electrically connecting two objects together includes a first object which has a first connective surface defined thereon, and a plurality of first electrical pads supported on the first connective surface. A second object has a second connective surface defined thereon which supports a plurality of second electrical pads configured to contact the first electrical pads. The first and second objects are configured to be electrically connected to each other by movement of the first object relative to the second object in a given direction and along a continuous path of movement which is substantially parallel to the first connective surface. The apparatus further includes an alignment member which is movably supported on the second object and which is configured to engage the second object when moved so as to substantially align the first electrical pads with the second electrical pads in order to facilitate contact there between.

Abstract: The invention includes a plurality of first electrical pads which are supported on a first object which is configured to be supported in a first position, and a plurality of second electrical pads which are supported on a second object which is configured to be supported in a second position and adjacent to the first object. The first electrical pads are configured to electrically contact the second electrical pads while the objects are supported in the respective positions so as to electrically connect the objects together. Each of the objects is configured to be removed from the respective first and second positions by movement along parallel paths of movement in a first direction and are configured to be installed in the respective positions by movement along the paths in a second direction which is opposite the first direction. Furthermore, each object is configured to be installed into, or removed from, its respective supported position while the other object remains supported in its respective position.

Abstract: An assembly housing for accepting an electroacoustical transducer having a rear face with terminal pins proceeding therefrom, contact surfaces thereon, and at least one sound admission opening, is formed by an acceptor plate which is disposed adjacent the rear face of the electroacoustical transducer, and a covering cap which is fitted over the radial edge of the acceptor plate. The acceptor plate has respective openings therein proceeding completely through the acceptor plate which respectively receive the terminal pins, and has blind holes therein which respectively receive springs in registration with the electrical contact surfaces of the electroacoustical transducer. The acceptor plate has a radially-proceeding sound admission channel therein, with one end in registration with the sound admission opening in the rear face of the transducer, and an opposite end in registration with a sound admission opening in the covering cap.